Stockscreener 앱 받기
6.92
0.14%
-0.010
시간 외 거래:
6.92
전일 마감가:
$6.93
열려 있는:
$6.98
하루 거래량:
499.05K
Relative Volume:
1.07
시가총액:
$459.19M
수익:
$555.06M
순이익/손실:
$-39.48M
주가수익비율:
-11.53
EPS:
-0.6
순현금흐름:
$29.05M
1주 성능:
+11.97%
1개월 성능:
-2.12%
6개월 성능:
-34.35%
1년 성능:
-8.95%
1일 변동 폭
$6.77
$7.21
1주일 범위
$5.81
$7.35
52주 변동 폭
$5.81
$14.38
Bioventus Inc Stock (BVS) Company Profile
명칭
Bioventus Inc
전화
(919) 474-6700
주소
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
BVS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
6.92 | 483.75M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
134.28 | 227.88B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.14 | 152.55B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
377.58 | 143.34B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.88 | 114.49B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.35 | 46.11B | 5.69B | 4.14B | 577.90M | 6.96 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-17 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-12-07 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2022-11-22 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2022-11-09 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2022-03-15 | 개시 | Craig Hallum | Buy |
| 2021-11-15 | 재개 | Morgan Stanley | Overweight |
| 2021-11-10 | 재개 | JP Morgan | Overweight |
| 2021-07-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-08 | 개시 | Canaccord Genuity | Buy |
| 2021-03-08 | 개시 | Goldman | Buy |
| 2021-03-08 | 개시 | JP Morgan | Overweight |
| 2021-03-08 | 개시 | Morgan Stanley | Overweight |
모두보기
Bioventus Inc 주식(BVS)의 최신 뉴스
Bioventus (NASDAQ:BVS) Upgraded by Wall Street Zen to "Strong-Buy" Rating - MarketBeat
Bioventus Inc. Crosses 200 Day MA — Signal or NoiseTarget Return Focused Trade Insights Shared - metal.it
Bioventus Earnings Call: Strong Growth and Resilience - TipRanks
Should Investors Capitalize on Bioventus' Earnings Outperformance Amid Industry Lags? - AInvest
Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
Bioventus Inc. (NASDAQ:BVS) Q2 2025 Earnings Call Transcript - Insider Monkey
Bioventus outlines path to $100M+ PNS revenue opportunity as new products receive clearance - MSN
Bioventus Q2 Earnings Call: Robust Growth and Strategic Resilience - AInvest
Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference - The Manila Times
Exclusive: Bioventus CEO Reveals Future Growth Plans at Major Healthcare Conference - Stock Titan
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Announces Target Price $15 - 富途牛牛
Bioventus Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Bioventus Inc. Reports Q2 2025 Financial Results - TipRanks
Bioventus Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:BVS) - Seeking Alpha
Bioventus Q2 2025: Key Contradictions Unveiled on Tariffs, Growth Projections, and Market Dynamics - AInvest
Bioventus Q2 2025 slides: 6% organic growth despite revenue dip, FDA clearance boosts outlook By Investing.com - Investing.com South Africa
Bioventus Q2 2025 slides: 6% organic growth despite revenue dip, FDA clearance boosts outlook - Investing.com
Bioventus: Q2 Earnings Snapshot - The Washington Post
Transcript : Bioventus Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Earnings call transcript: Bioventus Q2 2025 sees steady EPS, revenue beat - Investing.com Canada
Earnings call transcript: Bioventus Q2 2025 sees steady EPS, revenue beat By Investing.com - Investing.com South Africa
Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates - sharewise.com
Bioventus Inc. Provides Earnings Guidance for the Year 2025 - MarketScreener
Bioventus Inc Q2 2025 Earnings: Revenue Beats at $147.7M, EPS Mi - GuruFocus
Bioventus reports Q2 EPS 21c, consensus 20c - TipRanks
Bioventus Inc. SEC 10-Q Report - TradingView
Bioventus Q2 2025 swings to $0.11 EPS, trims debt with new 2030 loan | KAR SEC FilingForm 8-K - Stock Titan
Bioventus Reports Second Quarter Financial Results - TradingView
Bioventus earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Bioventus Q2 revenue dips 2.4%, organic growth 6.2% - MarketScreener
Bioventus Reports Second Quarter Financial Results | BVS Stock N - GuruFocus
Bioventus Q2 revenue down 2.4% YoY, EPS up 31%, cash ops up 71%. - AInvest
What To Expect From Bioventus Inc (BVS) Q2 2025 Earnings - GuruFocus
Bioventus enters into a new $400M credit agreement, lowering interest expenses - MSN
Bioventus Receives Positive Rating from Craig-Hallum, Analyst Maintains Buy Recommendation - AInvest
Bioventus Inc expected to post earnings of 21 cents a shareEarnings Preview - TradingView
Sector ETF Data Correlates with Strength in Bioventus Inc.Growth Based Investment Plan Guidance Highlighted - metal.it
Bioventus Secures $400 Million Credit Agreement - TipRanks
Bioventus secures $400mln credit agreement with lower interest margin. - AInvest
Bioventus Enters into a New $400 Million Senior Secured - GlobeNewswire
Bioventus Lands $400M Credit Deal: Saves $2M Annually with 75 BPS Rate Cut - Stock Titan
What is Bioventus Inc. company’s growth strategyExceptional market positioning - Jammu Links News
What are analysts’ price targets for Bioventus Inc. in the next 12 monthsExponential wealth increase - Jammu Links News
How does Bioventus Inc. compare to its industry peersInvest confidently with advanced analysis tools - Jammu Links News
How volatile is Bioventus Inc. stock compared to the marketBuild wealth faster with consistent growth stocks - Jammu Links News
Bioventus gets FDA nod for pain management devices - MSN
What institutional investors are buying Bioventus Inc. stockHigh-yield investments - Jammu Links News
How strong is Bioventus Inc. company’s balance sheetAchieve rapid wealth accumulation with smart picks - Jammu Links News
How does Bioventus Inc. generate profit in a changing economyUnlock expert insights for smarter investing - Jammu Links News
What are Bioventus Inc. company’s key revenue driversIdentify winners with top-tier analysis - Jammu Links News
Is Bioventus Inc. stock overvalued or undervaluedGet daily expert analysis for smarter investing - Jammu Links News
Bioventus Inc (BVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.17%
자본화:
|
볼륨(24시간):